U.S. Stem Cell, Inc. (USRM)

Market Cap	66.15K -97.4%
Revenue (ttm)	82.05K -59.1%
Net Income	-2.86M
EPS	-0.00
Shares Out	661.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,240
Average Volume	459,845
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0002
Beta	-128.54
RSI	54.37
Earnings Date	Apr 14, 2026

About U.S. Stem Cell

U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: USRM

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$2.86 million, -13.06% less than in 2021.